On May 5, 2014, the U.S. Food and Drug Administration (FDA) expanded the indication of SYNRIBO to allow for home administration.
SYNRIBO is a prescription medicine used to treat adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) who are no longer responding to and/or who could not tolerate, two or more tyrosine kinase inhibitors (TKI).
The updated labeling for the product gives prescribers the option to allow patients to administer SYNRIBO therapy at home.
Previously, it was necessary for adults living with chronic or accelerated phase CML who were prescribed SYNRIBO to travel to their doctor’s office twice a day during active treatment to receive their therapy.
The administration schedule was burdensome for some patients and their caregivers and created a potential barrier to treatment. According to the American Cancer Society, a little more than 10 percent of leukemia diagnoses each year are CML, which affects the blood and bone marrow.
SYNRIBO is manufactured by Teva Pharmaceutical Industries Ltd. For full prescribing information, visit the manufacturer’s website.